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Gd-EOB-DTPA is a hepatocyte-specific MRI contrast agent. Due to its hepatocyte-specific uptake and
paramagnetic properties, functioning areas of the liver exhibit shortening of the T1 relaxation time. We
report the potential use of T1 relaxometry of the liver with Gd-EOB-DTPA-enhanced magnetic resonance
imaging (MRI) for estimating the liver function as expressed by the MELD score. 3 TMRI relaxometry was
performed before and 20 min after Gd-EOB-DTPA administration. A strong correlation between changes
in the T1 relaxometry and the extent of liver disease, expressed by the MELD score, was documented.
Reduced liver function correlates with decreased Gd-EOB-DTPA accumulation in the hepatocytes during
the hepatobiliary phase. MRI-based T1 relaxometry with Gd-EOB-DTPA may be a useful method for
assessing overall and segmental liver function.
T
he liver-specific magnetic resonance imaging (MRI) contrast agent gadolinium-ethoxybenzyl diethylene-
triaminepentaacetic acid (Gd-EOB-DTPA, PrimovistH; Bayer Schering Pharma, Berlin, Germany) is pref-
erentially used for detecting and characterizing focal hepatic lesions and for evaluating the biliary system1.
After administration, Gd-EOB-DTPA is eliminated from the body in almost equal amounts via the following two
pathways: organic anion transporting polypeptide (OATP)-mediated uptake in the hepatocytes with subsequent
excretion into the biliary tract and glomerular filtration through the kidneys2,3. Hence, Gd-EOB-DTPA produces
both dynamic perfusion and liver-specific hepatobiliary MR images4.
In animal models, there is an inverse correlation between experimentally induced hepatic dysfunction and Gd-
EOB-DTPA enhancement of the liver parenchyma5,6. Moreover, the reduced signal intensity after Gd-EOB-
DTPA administration has been linked to down-regulated membrane transporter expression in cirrhotic livers7.
Hepatic parenchymal enhancement in patients with impaired hepatocyte function decreases during the
hepatobiliary phase (HP)8,9. Few studies have investigated the potential clinical factors that influence the liver
parenchyma signal intensity onGd-EOB-DTPA-enhancedMR images10–13. However, in addition to themeasure-
ment of relative signal intensities of the liver enhancement effects, MR relaxometry has recently received
increased attention as a tool for quantitative analyses.
Because of the hepatocellular uptake of Gd-EOB-DTPA and its paramagnetic properties, functioning areas of
the liver show T1 shortening in the longitudinal relaxation times14. Based on these T1 shortening effects, the
quantitative evaluation of hepatocellular Gd-EOB-DTPA uptake allows for the direct measurement of liver
function15,16. Therefore, we determined the T1 relaxation times before and 20 min after contrast medium admin-
istration in patients with and without diffuse liver disease.
The purpose of this study was to determine whether post-Gd-EOB-DTPA T1 relaxometry at 3 T is affected by
the degree of liver disease, as expressed by the model for end-stage liver disease (MELD) score, a commonly
applied scoring system for liver function.
Results
No significant difference in the age distribution was found between the patient group with normal liver function













should be addressed to
M.H. (michael.
haimerl@ukr.de)
SCIENTIFIC REPORTS | 4 : 5621 | DOI: 10.1038/srep05621 1
Themean T1 relaxation times of non-enhancedMRI (762.7 ms6
149.0 ms) and Gd-EOB-DTPA-enhanced MRI (340.0 ms 6
118.8 ms) were significantly different (p , 0.001) (all patients).
The pre-contrast mean T1 relaxation times were not significantly
different between the groups with MELD # 10 (760.7 ms 6
145.3 ms), MELD 11–18 (760.4 ms 6 152.6 ms), and MELD . 18
(803.2 6 ms 6 196.0 ms) (MELD # 10 to MELD 11–18, p 5 1.0,
95% CI [258.01 to 58.66]; MELD # 10 to MELD . 18, p 5 0.632,
95% CI [2151.92 to 67.04], MELD 11–18 toMELD. 18, p 5 0.670,
95% CI [2160.99 to 75.46]).
After Gd-EOB-DTPA administration, the T1 relaxation times
decreased significantly in the respective groups (p , 0.001).
Comparison of the patient group with MELD # 10 and the patient
groups with impaired liver function (MELD 11–18 andMELD. 18)
showed significant increases in the mean T1 relaxation times with
increasing liver damage (MELD # 10 to MELD 11–18, p , 0.001,
95%CI [2156.65 to278.91];MELD# 10 toMELD. 18, p, 0.001,
95% CI [2313.69 to 2167.78], MELD 11–18 to MELD . 18, p 5
0.001, 95% CI [2201.73 to 244.17]). The shortening of the T1
relaxation times was significantly lower for patients with higher
MELD scores (Table 2, Figure 1).
Twenty minutes after Gd-EOB-DTPA administration, we found a
constant, significant decrease in the reduction rates of the T1 relaxa-
tion times. The reduction rates of the T1 relaxation times were sig-
nificantly higher for patients withMELD# 10 (59%6 11%) than for
patients withMELD11–18 (44%6 15%) andwithMELD. 18 (30%
6 11%) (MELD # 10 to MELD 11–18, p , 0.001, 95% CI [0.11 to
0.20]; MELD# 10 to MELD. 18, p, 0.001, 95% CI [0.20 to 0.38];
MELD 11–18 to MELD . 18; p , 0.001, 95% CI [0.04 to 0.22])
(Table 2, Figure 2). Examples of the pre- and post-contrast T1 maps
for all groups were color-coded and are shown in Figure 3.
Using receiver-operating characteristics analysis, we determined
the cut-off values and area under the curve (AUC) values for differ-
entiating patients withMELD# 10 from patients with impaired liver
function and for differentiating between different grades of liver
function based on the reduction rate. The cut-off values of the
post-T1 relaxation times for distinguishing patients with MELD #
10 from patients with MELD 11–18 and MELD. 18 were 341.0 ms
and 419.5 ms, respectively; the corresponding cut-off value for dis-
tinguishing between patients with MELD 11–18 and those with
MELD. 18 was 488.4 ms. The cut-off values for the reduction rate
of the T1 relaxation times to differentiate patients with MELD# 10
from the MELD 11–18 and MELD . 18 patient groups were 50.0%
and 47.3%, respectively; the corresponding cut-off value for differ-
entiating between the MELD 11–18 patient group and the MELD.
18 patient group was 35.6%. Table 3 summarizes the respective cut-
off values for the T1 relaxation times and reduction rates as well as
the corresponding AUC values, sensitivities, and specificities.
Discussion
In this study, we compared the quantitative characterization of the
T1 relaxation time changes in unenhanced and Gd-EOB-DTPA-
enhanced 3 T MRI with the MELD score, which is a commonly
applied score for liver function. The T1 relaxation time is a tissue
parameter that depends on the tissue’s physical, chemical, and bio-
logical characteristics. The results of our study show that the T1
relaxation time of the Gd-EOB-DTPA-enhanced liver parenchyma
is a suitable method for distinguishing between healthy people and
patients with liver disease.
Several scoring systems (Child-Pugh,MELD, orMELD-Na scores;
ICG test) are widely accepted for assessing hepatic dysfunction17–19.
The MELD score incorporates objective parameters, such as the
creatinine and bilirubin levels, the pro-thrombin time, and inter-
national normalized ratio (INR). The MELD score is therefore not
dependent on subjective clinical parameters such as hepatic ence-
phalopathy. This condition — in addition to the albumin and bilir-
ubin levels, INR, and ascites—defines theChild-Pugh score, creating
problems due to its clinical parameter subjectivity and restricted
discriminatory properties20–22. The MELD score has primarily been
used for allocating organs for liver transplantation. Subsequently,
this score has been validated as an accurate predictor of both the
short-term and medium-term survival of patients with any type of
liver disease, especially patients with fulminant hepatic failure, alco-
holic hepatitis, hepatocellular carcinoma, liver infection, liver cirrho-
sis, or other chronic liver disease23,24.
Several studies have reported the evaluation of hepatic function
based on the direct measurement of biliary enhancement25–27. The
time and degree of Gd-EOB-DTPA biliary enhancement are related
to hepatic function; the biliary enhancement is significantly weaker
and delayed in patients with liver disease. Still, the most common
approach for assessing hepatic function on Gd-EOB-DTPA-
enhanced MRI is the direct or corrected measurement of hepatic
parenchymal signal intensity, which is reduced in patients with hep-
atic dysfunction18,28–30. Based on a routine clinical imaging protocol,
Table 1 | Patient characteristics
Group All (n 5 233) MELD # 10(n 5 176) MELD 11–18 (n 5 46) MELD . 18 (n 5 11) P-value
Age (years) 59.5 6 12.9 59.8 6 13.0 60.3 6 13.6 58.7 6 8.2 p 5 0.93
Gender
men 158 (68%) 110 (63%) 40 (87%) 8 (73%) p 5 0.006
women 75 (32%) 66 (38%) 6 (13%) 3 (27%)
Height (m) 1.72 6 0.09 1.72 6 0.09 1.75 6 0.07 1.73 6 0.09 p 5 0.044
Weight (kg) 82.7 6 19.1 81.6 6 19.1 87.6 6 18.1 81.6 6 21.0 p 5 0.16
Values indicate the mean 6 standard deviation.
MELD (model for end-stage liver disease) score.
Table 2 | T1 relaxation times and reduction rates of the liver in non-enhanced MRI and Gd-EOB-DTPA-enhanced MRI
All (n 5 233) MELD # 10 (n 5 176) MELD 11–18 (n 5 46) MELD . 18 (n 5 11)
T1pre (ms) 762.7 6 149.0 760.7 6 145.3 760.4 6 152.6 803.2 6 196.0
T1post (ms) 340.0 6 118.8 305.4 6 92.4 423.1 6 124.2 546.1 6 95.4
Reduction rate (%) 55 6 14 59 6 11 44 6 15 30 6 11
Values indicate the mean 6 standard deviation.
MELD (model for end-stage liver disease) score.
T1pre, T1 relaxation time before Gd-EOB-DTPA administration.
T1post, T1 relaxation time 20 min after Gd-EOB-DTPA administration.
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these approaches are simple, easy to implement in clinical practice
and do not require additional MR sequences, mathematical model-
ing or sophisticated analysis of MR signal characteristics. However,
the assessment of biliary enhancement is strongly influenced by bili-
ary fluid dynamics, and signal intensitymeasurements reflect relative
values depending onmany technical parameters, such as the potency
of the radiofrequency amplifiers, the receiver coil and the pulse
sequence designed by different MRI system manufacturers19. Addi-
tionally, the signal intensity and gadolinium concentration do not
have a linear pattern; therefore, the signal intensity measurements
may not directly correlate with the gadolinium concentration31.
We used T1 relaxometry, indicating the absolute values of the T1
relaxation times, for the quantitative comparison of the pre-contrast
and post-contrast enhancement of the hepatic parenchyma, which is
not affected by those limitations.
In our study, the T1 relaxation times for non-enhanced MRI did
not show any significant differences between the patients with
MELD # 10, indicating no liver disease, those with MELD 11–18,
indicating moderate liver disease, and the group with MELD . 18,
indicating severe liver disease32. However, the absolute T1 relaxation
times of patients with severe liver disease tended to be higher than
for other MELD score groups, although this effect was not signifi-
cant (MELD # 10: 760.7 ms, MELD 11–18: 760.4 ms; and MELD
. 18: 803.2 ms). These results were in accordance with other pub-
lished data on liver fibrosis and cirrhosis in non-enhanced MR
imaging19,33,34. Increasing values for the T1 relaxation times have
been found in patients with impaired liver function. These increases
are caused by the pathophysiological processes of induced liver
fibrogenesis, which is characterized by inflammation, edema, and
Figure 1 | Pre- and post-contrast T1 relaxation times. Boxplots indicating the T1 relaxation times before (pre) and after (post) Gd-EOB-DTPA
administration in patients with normal liver function (MELD score# 10) and patients with impaired liver function (MELD score 11–18 andMELD score
. 18). After Gd-EOB-DTPA administration, the reduction in the T1 relaxation times was highly significant (p# 0.001) in patients withMELD scores of
#10 and 11–18 and significant (p # 0.05) for patients with severely impaired liver function (MELD . 18). MELD (model for end-stage liver disease)
score. Data are given as the mean T1 relaxation times 6 standard deviation. Tukey-adjusted post-hoc pairwise comparisons were used to compare the
groups. ***p # 0.001, *#0.05.
Figure 2 | Reduction rates for the T1 relaxation times. Boxplots of the
reduction rates for the T1 relaxation times of the liver in patients with
normal liver function, MELD score # 10, and patients with impaired liver
function, MELD score 11–18 and MELD score . 18. Reduction rates were
significantly reduced with an increasing degree of liver damage. The
reduction rate (%) was calculated as follows: ([T1pre 2 T1post]/T1pre)3 100;
here, T1pre is the T1 relaxation time before Gd-EOB-DTPA administration,
and T1post is the T1 relaxation time after Gd-EOB-DTPA administration.
MELD (model for end-stage liver disease) score. Data are given as the mean
T1 reduction rate 6 standard deviation. Tukey-adjusted post-hoc pairwise
comparisons were used to compare the groups. ***p # 0.001.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5621 | DOI: 10.1038/srep05621 3
synthesis of the extracellular matrix. This increase may be a result of
the augmented hepatic water content that is caused by edema and
the synthesis of collagen fibers, in which protons are less abundant
and tightly bound. An additional reason may be the increase in the
ratio of the free to bound water and the structure of intracellular
water35,36. However, in the clinical situation, liver cirrhosis is a
chronic condition that is not commonly combined with edema
and acute inflammation. In contrast, other previous studies did
not observe a correlation between liver disease and the T1 relaxation
times, and some showed a decrease in the unenhanced T1 relaxation
time with an increasing degree of cirrhosis37–39 These controversial
findings indicate that non-enhanced T1 relaxometry is unlikely to
be an appropriate method for detecting and staging liver disease.
Twenty minutes after Gd-EOB-DTPA administration, the mean
T1 relaxation times of the patients in the control group were signifi-
cantly lower than those of the patients with liver disease. Our results
support the conclusion that the post-contrast T1 relaxation times
may facilitate the differentiation between liver disease and normal
Figure 3 | T1 relaxation time color-coded T1 maps. (A–F) T1 maps calculated from two TurboFlash sequences (TI 5 400 ms, 1000 ms) were obtained
before (A, C, E) and 20 minutes after Gd-EOB-DTPA administration (B, D, F) in a patient with aMELD score of 6 (man, 44 years of age, height: 1.86 m,
weight: 99 kg; A, B), a patient with aMELD score of 14 (man, 71 years of age, height: 1.75 m, weight: 91 kg; C, D), and a patient with aMELD score of 20
(man, 50 years of age, height: 1.80 m, weight: 92 kg; E, F). Themean T1 relaxation times of liver parenchyma were as follows: 751.4 ms (A), 216.0 ms (B),
718.7 ms (C), 321.8 ms (D), 785.4 ms (E), and 628.3.0 ms (F). The reduction rates of the T1 relaxation timewere 71% (A, B), 41% (C,D), and 20% (E, F).
In the control group (MELD 5 6), the T1 relaxation time on the T1mapping color-codedmaps of the liver on post-contrast MRI (B) showed amarkedly
darker color distribution of the liver parenchyma than that on the pre-contrast mapping image (A), indicating strong Gd-EOB-DTPA-induced
shortening of the T1 relaxation time 20 min after contrast medium administration. With an increasing degree of liver damage, the color distribution in
liver parenchyma was visually confirmed to show a smaller change on the post-contrast T1 maps.
www.nature.com/scientificreports
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liver as well as help with the evaluation of the degree of liver function.
However, pre-contrast T1 relaxation times may modify the shor-
tened T1 relaxation times after Gd-EOB-DTPA administration for
patients with MELD # 10 and the prolonged post-contrast T1
relaxation times for patients with liver disease. Therefore, the reduc-
tion rate in the T1 relaxation times was calculated to determine the
uptake of Gd-EOB-DTPA in the liver parenchyma, and there was a
significantly lower reduction rate in the T1 relaxation times for
patients with liver disease (MELD 11–18, 44%; MELD . 18, 30%)
than for patients with normal liver function (MELD # 10, 59%).
We performed ROC analysis to estimate the cut-off values for
differentiating healthy patients from patients with impaired liver
function. The cut-off value for the reduction rate to distinguish
patients with normal liver function from patients with moderately
impaired liver function (MELD 11–18) was 50.0%. Therefore, the
shortening (by half) of the T1 relaxation time after Gd-EOB-DTPA
administration compared with the pre-contrast T1 relaxation time
could serve as a possible point of reference for impaired liver func-
tion. The assessment of liver function plays a crucial role in many
clinical settings. Most of the available liver tests provide an overall
evaluation of global liver function. However, the assessment of
regional or remnant hepatic function is important in both presurgi-
cal evaluations, before segmental liver resection, to avoid post-
operative liver failure and in monitoring liver diseases that affect
the liver in a non-homogeneous way40.
Our study has some limitations. For example, we compared the
hepatic uptake of Gd-EOB-DTPAwith only theMELD score.We did
not use any other test, such as the ICG test, for evaluating liver
function. ROI placement may also be an alternative method because
of the potentially heterogeneous distribution of the parenchymal
changes and the limited patient-to-patient reproducibility. How-
ever, averaging three repetitive measurements across a large area of
the liver parenchyma should yield representative values. The lack of
histopathology is another potential limitation because of the pres-
ence of early parenchymal changes, such as steatosis. Moreover, T1
relaxation has been shown to strongly depend on the strength of the
magnetic field41; T1 relaxation times are reportedly longer and T1
shortening effects of contrast material are more prominent at 3 T
than at 1.5 T. Compared with the direct hepatic signal intensity
method, the MR relaxometry method requires additional scan
sequences and dedicated software to calculate the relaxation times.
However, the additional use of our liverMRI protocol to acquire pre-
and post-contrast T1 relaxation times is limited to 32 s.
In conclusion, because T1 relaxometry for pre- and post-Gd-EOB-
DTPA MRI is a useful parameter for indicating the degree of liver
disease, it may have the potential to become a novel tool for mon-
itoring liver function.
Methods
Patients. We obtained the approval of an institutional review board for this
prospective study and written informed consent from all study participants before
enrollment. Between June 2012 andAugust 2013, 302 consecutive patients underwent
Gd-EOB-DTPA-enhanced MR imaging of the liver, including T1 mapping, for the
presence of a suspicious liver lesion detected during previous computed tomographic
or ultrasonographic examinations, for suspected chronic liver disease, or as part of a
scheduled follow-up examination for known liver disease. Patients were excluded if
they had previously received local treatment for liver disease (n 5 29) or if they were
unable to complete the entire MR imaging examination (n 5 40). A total of 233
patients (158 men; 75 women; mean age, 59.9 6 13.0 years) were included in this
study. The severity of liver disease was classified according to the MELD score, an
internationally accepted scoring system for assessing the severity of chronic liver
Table 3 | ROC analysis indicating the various cut-off values and diagnostic performance for differentiating the control group (MELD# 10)
from patients with impaired liver function (MELD 11–18 and MELD . 18)
Cut-offs T1post (ms)
AUC T1post (sensitivity,
specificity) Cut-off reduction rate (%)
AUC reduction rate
(sensitivity, specificity)
MELD # 10 to MELD 11–18 341.0 0.80 (78%, 73%) 50.0% 0.79 (72%, 81%)
MELD # 10 to MELD . 18 419.5 0.95 (91%, 89%) 47.3% 0.97 (100%, 85%)
MELD 11–18 to MELD . 18 488.4 0.81 (82%, 83%) 35.6% 0.75 (73%, 67%)
Values indicate the mean 6 standard deviation.
MELD (model for end-stage liver disease) score.
AUC (area under the receiver operating characteristic curve).
T1post, T1 relaxation time 20 min after Gd-EOB-DTPA administration.
Figure 4 | Flowchart of the included patients. Three hundred two patients
underwent Gd-EOB-DTPA-enhanced MRI. Twenty-nine patients were
excluded because of previous local liver treatment, and 40 patients were
unable to finish the entire MRI protocol. In total, 233 patients were
included, with 176 having normal liver function and a MELD score # 10
and 57 patients having impaired liver function (MELD 11–18, n 5 46;
MELD . 18, n 5 11).
www.nature.com/scientificreports
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disease. The MELD score was calculated with a standard formula that adds multiples
of the natural logarithm (ln) to the values for the international ratio of coagulation
(INR), creatinine, and bilirubin as follows: 11.2 3 ln(INR) 1 9.57 3 ln(creatinine, in
milligrams per deciliter)1 3.783 ln(bilirubin, inmilligrams per deciliter)1 6.43 (an
intercept). The lower limit of all variables was set to 1, and creatinine was capped at 4
if patients received renal replacement therapy20.
Thus, patients were classified as follows: patients with a MELD score# 10 (MELD
# 10, n 5 176), representing a healthy population; patients with a MELD score of 11
to 18 (MELD 11–18, n 5 46), indicating moderate liver disease; and patients with a
MELD score . 18 (MELD . 18, n 5 11), indicating severe liver disease32. The
parameters used to calculate the MELD score were acquired within 5 days before or
after the MRI examination. The patient flowchart is shown in figure 4.
MR imaging protocol.All imaging procedures were conducted with a clinical, whole
body 3 T system (Magnetom Skyra, Siemens Healthcare, Erlangen, Germany) using a
combination of body and spine array coil elements (18-channel body matrix coil, 24-
channel spine matrix coil) for signal reception. We obtained two TurboFLASH
sequences (inversion time [TI], 400 ms and 1000 ms; repetition time [TR], 4000 ms;
echo time [TE], 1.16 ms; flip angle 8u; slice thickness, 6 mm; FOV 400 mm 3
400 mm; matrix size, 1923 192) in a single breath hold. We acquired T1maps of the
porta hepatis before and 20 min after Gd-EOB-DTPA injection in addition to the
routine Gd-EOB-DTPA MRI protocol; the peak of liver signal intensity has been
shown to occur 20 min after Gd-EOB-DTPA administration2,42–44. The liver-specific
contrast agent (Primovist; Bayer Schering Pharma AG, Berlin, Germany) was
injected, body weight-adapted (0.025 mmol/kg body weight), via an intravenous
bolus injection with a flow rate of 1 mL/s and flushed with 20 mL of NaCl.
Image analysis. Dedicated software was used to generate the parametric T1 maps
(Siemens Healthcare, Erlangen, Germany) based on the acquired TurboFLASH
sequences before and 20 min after Gd-EOB-DTPA administration.
To assess the T1 relaxation times of the liver, we used the region of interest (ROI)
measurement in the T1 mapping images before and after Gd-EOB-DTPA admin-
istration. Two ROIs were placed in the right lobe, and one in the left lobe. Special care
was taken to avoid focal hepatic lesions (e.g., cysts and hemangiomas) and major
branches of the portal or hepatic veins and to avoid imaging artifacts. The mean T1
value for the 3 ROIs was considered the representative T1 value for the liver. ROIs of
identical size and shape were placed at the same imaging sequence in T1 maps before
and after Gd-EOB-DTPA administration.
We calculated the shortening of the T1 relaxation times for each group, indicating
the absolute change in the T1 values between pre- and post-Gd-EOB-DTPA
enhancement:
Shortening of T1 relaxation time~T1pre{T1post
Additionally, the reduction rate, indicating the relative change in the T1 values
between the pre- and post-Gd-EOB-DTPA enhancement, was calculated as follows:




x 100 %ð Þ
Here, T1pre is the T1 relaxation time before Gd-EOB-DTPA administration, and
T1post is the T1 relaxation time after Gd-EOB-DTPA administration. We used the
visualization tool of the open source OsiriX imaging software (OsiriX v.5.5) to gen-
erate color-coded maps.
Statistical analysis. Data are expressed as the mean 6 standard deviation (SD). We
used a one-way analysis of variance (ANOVA) to analyze the differences between
patients with normal liver function and two patient groups with progressively
impaired liver function. Post hoc pair-wise comparisons were made with the Tukey
procedure. We used ROC analyses to differentiate between patient groups and
estimated the optimal cut-off according to the Youden Index. Estimates for the area
under the curve (AUC) and the true classification rates are reported. All tests were
two-sided, and values of p , 0.05 indicate significant difference. All statistical
analyses were performed with IBM SPSS Statistics (version 21, Chicago, IL) and R
3.0.1.
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